ScoreWhy is Coya Therapeutics, Inc. ?
1
Flat results in Jun 25
- NET SALES(HY) At USD 0.42 MM has Grown at -88.13%
- PRE-TAX PROFIT(Q) At USD -6.09 MM has Fallen at -110.78%
- NET PROFIT(Q) At USD -6.09 MM has Fallen at -110.78%
2
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -6.77%, its profits have fallen by -74.7%
3
High Institutional Holdings at 37.85%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 1.86% over the previous quarter.
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -6.77% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Coya Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Miscellaneous should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Miscellaneous)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Coya Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Coya Therapeutics, Inc.
-0.66%
-0.22
65.78%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
5.55%
EBIT Growth (5y)
-284.91%
EBIT to Interest (avg)
-7.54
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.06
Sales to Capital Employed (avg)
0.12
Tax Ratio
4.03%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
37.85%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.94
EV to EBIT
-3.23
EV to EBITDA
-3.23
EV to Capital Employed
-29.02
EV to Sales
17.02
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-51.35%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend3What is working for the Company
NET PROFIT(HY)
Higher at USD -13.4 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -105.11 %
-26What is not working for the Company
NET SALES(HY)
At USD 0.42 MM has Grown at -88.13%
PRE-TAX PROFIT(Q)
At USD -6.09 MM has Fallen at -110.78%
NET PROFIT(Q)
At USD -6.09 MM has Fallen at -110.78%
OPERATING CASH FLOW(Y)
Lowest at USD -16.47 MM
ROCE(HY)
Lowest at -63.99%
Here's what is working for Coya Therapeutics, Inc.
Debt-Equity Ratio
Lowest at -105.11 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Here's what is not working for Coya Therapeutics, Inc.
Net Sales
At USD 0.42 MM has Grown at -88.13%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (USD MM)
Pre-Tax Profit
At USD -6.09 MM has Fallen at -110.78%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -6.09 MM has Fallen at -110.78%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Operating Cash Flow
Lowest at USD -16.47 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
